The role of c-FLIP in cisplatin resistance of human bladder cancer cells

Journal of Urology

Volumn 189, Issue 6, 2013, Pages 2327-2334

  Lee, Sangchul ^a   Yoon, Cheol Yong ^b   Byun, Seok Soo ^a   Lee, Eunsik ^c   Lee, Sang Eun ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

carcinoma; cisplatin; drug resistance; gene expression; urinary bladder

Indexed keywords

CASPASE 2; CASPASE 9; CISPLATIN; DEATH RECEPTOR; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OLIGONUCLEOTIDE; PROTEIN BID; SMALL INTERFERING RNA; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER RESISTANCE; CELL ASSAY; CELL COUNT; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TARGETING; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN TARGETING; VALIDATION PROCESS; WESTERN BLOTTING;

BLOTTING, WESTERN; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROARRAY ANALYSIS; PHARMACOGENETICS; RNA, SMALL INTERFERING; ROLE; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS;

EID: 84877627415     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.01.003     Document Type: Article

References (24)

1. H. von der Maase, L. Sengelov, J.T. Roberts Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 23 2005 4602
2. H. von der Maase, S.W. Hansen, J.T. Roberts Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 2000 3068
3. F.A. Yafi, S. North, W. Kassouf First- and second-line therapy for metastatic urothelial carcinoma of the bladder Curr Oncol 18 2011 e25
4. S. Krege, V. Rembrink, C. Borgermann Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study J Urol 165 2001 67
5. K. Kanai, E. Kikuchi, T. Ohigashi Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy Int J Clin Oncol 13 2008 510
6. J. Carles, E. Esteban, M. Climent Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer Ann Oncol 18 2007 1359
7. J. Bellmunt, C. Theodore, T. Demkov Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract J Clin Oncol 27 2009 4454
8. C.A. Rabik, M.E. Dolan Molecular mechanisms of resistance and toxicity associated with platinating agents Cancer Treat Rev 33 2007 9
9. H.J. Cho, J.K. Kim, K.D. Kim Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells Cancer Lett 237 2006 56
10. J.K. Kim, K.D. Kim, E. Lee Up-regulation of Bfl-1/A1 via NF-kappaB activation in cisplatin-resistant human bladder cancer cell line Cancer Lett 212 2004 61
11. S.S. Byun, S.W. Kim, H. Choi Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities BJU Int 95 2005 1086
12. F.H. Igney, P.H. Krammer Death and anti-death: tumour resistance to apoptosis Nat Rev Cancer 2 2002 277
13. M. Bagnoli, S. Canevari, D. Mezzanzanica Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer Int J Biochem Cell Biol 42 2010 210
14. F. Ewald, N. Ueffing, L. Brockmann The role of c-FLIP splice variants in urothelial tumours Cell Death Dis 2 2011 e245
15. S.Y. Sun, X. Liu, W. Zou The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells J Biol Chem 282 2007 18800
16. L. Galligan, D.B. Longley, M. McEwan Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP Mol Cancer Ther 4 2005 2026
17. M. Kartalou, J.M. Essigmann Mechanisms of resistance to cisplatin Mutat Res 478 2001 23
18. A.R. Safa, T.W. Day, C.H. Wu Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy Curr Cancer Drug Targets 8 2008 37
19. A. Dutton, J.D. O'Neil, A.E. Milner Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death Proc Natl Acad Sci U S A 101 2004 6611
20. K.M. Rogers, M. Thomas, L. Galligan Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells Mol Cancer Ther 6 2007 1544
21. D.B. Longley, T.R. Wilson, M. McEwan c-FLIP inhibits chemotherapy-induced colorectal cancer cell death Oncogene 25 2006 838
22. D.A. Sharp, D.A. Lawrence, A. Ashkenazi Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis J Biol Chem 280 2005 19401
23. T.W. Day, S. Huang, A.R. Safa c-FLIP knockdown induces ligand-independent DR5-, FADD-, caspase-8-, and caspase-9-dependent apoptosis in breast cancer cells Biochem Pharmacol 76 2008 1694
24. P. Korkolopoulou, A. Goudopoulou, G. Voutsinas c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations Urology 63 2004 1198